Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

New treatment options in allergic rhinitis: patient considerations and the role of ciclesonide

Authors F Braido, C Lagasio, IMG Piroddi, I Baiardini, GW Canonica

Published 11 April 2008 Volume 2008:4(2) Pages 353—361

DOI https://doi.org/10.2147/TCRM.S1266

F Braido, C Lagasio, IMG Piroddi, I Baiardini, GW Canonica

Allergy and Respiratory Diseases Department, University of Genoa, Italy

Abstract: Allergic rhinitis (AR) is a chronic inflammatory respiratory disease affecting 5%–50% of the worldwide population and its prevalence is increasing (Herman 2007). In addition, AR is associated with asthma and other co-morbidities such as conjunctivitis and sinusitis. The main symptoms are nasal congestion, rhinorrea, sneezing, itching, and post-nasal drainage induced after allergen exposure by an IgE-mediated inflammation of the membranes lining the nose. AR is not a life-threatening disease, but it has been shown to have a significant impact on quality of life. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines propose a classification of AR in intermittent and persistent, each graded as mild or moderate-severe, and provide a stepwise approach to the treatment. Inhaled steroids and antihistamine are the main tools in AR therapy but more safe and effective drugs are, however, needed. Inhaled steroid ciclesonide appears to be safe and effective.

Keywords: ciclesonide, allergic rhinitis, asthma, quality of life

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Management of postoperative ileus: focus on alvimopan

Eric L Marderstein, Conor P Delaney

Therapeutics and Clinical Risk Management 2008, 4:965-973

Published Date: 10 October 2008

Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate

Ismail A Mohammed, Alastair J Hutchison

Therapeutics and Clinical Risk Management 2008, 4:887-893

Published Date: 10 October 2008

A systematic approach of tracking and reporting medication errors at a tertiary care university hospital, Karachi, Pakistan

Khurshid Khowaja, Rozmin Nizar, Rashida J Merchant, Jacqueline Dias, Irma Bustamante-Gavino, Amina Malik

Therapeutics and Clinical Risk Management 2008, 4:673-679

Published Date: 8 August 2008

Fospropofol disodium injection for the sedation of patients undergoing colonoscopy

Benjamin E Levitzky, John J Vargo

Therapeutics and Clinical Risk Management 2008, 4:733-738

Published Date: 8 August 2008

Early ischemic CT changes before thrombolysis: The influence of age and diabetes mellitus

Lars Thomassen, Ulrike Waje-Andreassen, Halvor Naess

Therapeutics and Clinical Risk Management 2008, 4:699-703

Published Date: 8 August 2008

Single-day treatment for orolabial and genital herpes: a brief review of pathogenesis and pharmacology

Sapna Modi, Livia Van, Aron Gewirtzman, Natalia Mendoza, Brenda Bartlett, et al

Therapeutics and Clinical Risk Management 2008, 4:409-417

Published Date: 11 April 2008

Raltegravir: first in class HIV integrase inhibitor

Zelalem Temesgen, Dawd S Siraj

Therapeutics and Clinical Risk Management 2008, 4:493-500

Published Date: 11 April 2008